Table 1.
Characteristics of included studies.
| References | Country | Age (mean or median) | Cancer group | Control group | Sample type | Control type | Method | Methylation frequency of OPCML associated with other clinicopathological parameters | ||
|---|---|---|---|---|---|---|---|---|---|---|
| M | U | M | U | |||||||
| Wang et al. (2015) | China | Cancer, 54.06 years. Benign, 33.95 years. Healthy, 46.17 years. | 64 | 7 | 11a | 112a | Serum | BOT&NT | MSP | FIGO stage: I/II (33/39), III/IV (30/32). |
| Xing et al. (2015) | China | NR | 27 | 8 | 2 | 9 | Tissues | NT | CCP-based FRET | Age: <60 years (23/28), ≥60 years (4/7). FIGO stage: I/II (5/11), III/IV (22/24). Histological type: serous (22/26), others (5/9)b. Grade of differentiationc: High-grade serous (19/21), others (8/14) Ascites: positive (21/24), Negative (6/11). CA125: >200 U/mL (21/25), <200 U/mL (6/10) |
| Zhou et al. (2014a) | China | Cancer and normal, 50 years. | 39 | 6 | 0d | 40d | Tissues | NT | MSRE-PCR | Tissues FIGO stage: I/II (5/10), III/IV (34/35). Histological type: serous (18/20), others (21/25)e. Tumor differentiation: Well and moderately differentiated (10/16), Poorly differentiated (29/29). |
| Healthy, 50 years. | 36 | 9 | 0d | 20d | Serum | NT | MSRE-PCR | Serum FIGO stage: I/II (5/10), III/IV (31/35). Histological type: serous (17/20), others (19/25)e. Tumor differentiation: Well and moderately differentiated (9/16), Poorly differentiated (27/29). | ||
| Zhou et al. (2014b) | China | Cancer, 54 years. Benign, 53 years. Normal, 54 years. | 80 | 22 | 0f | 30f | Tissues | NT | MSP | Age: <55 years (39/54), ≥55 years (41/48). Pathological stage*: I/II (31/44), III/IV (49/58). Histological typeb: serous (42/57), others (38/45). |
| – | – | 28f | 57f | Tissues | BOT | MSP | ||||
| Czekierdowski et al. (2006) | Poland | NRg | 20 | 23 | 0 | 4 | Tissues | NT | MSP | FIGO stage: I/II (4/5), III/IV (16/38). Histological type: serous (8/15), others (12/28)h. Histological Grading: G1+G2 (11/20), G3 (9/23)k |
| Zhang et al. (2006) | China | Cancer, 51.5 years. Benign, 39.0 years. Normal, 46.5 years. | 32 | 40 | 0 | 20 | Tissues | NT | Restriction enzyme cut | |
| 0 | 17 | Tissues | BOT | Restriction enzyme cut | ||||||
| Liu et al. (2008)i | China | Cancer, 53.8 years. Normal, 53.2 years. | 30 | 33 | 0 | 20 | Tissues | NT | MSP | FIGO stage: I/II (2/22), III/IV (16/41). Histological type: serous (20/34), others (10/29)j. Grading: Well and Moderately differentiated (6/36), Poorly differentiated (12/27) |
| 2 | 13 | Tissues | AT | |||||||
M, methylation; U, unmethylation; BOT, benign ovarian tissues or blood; NT, normal ovarian tissues or blood of cancer-free patients or healthy people; AT, Adjacent non-cancerous ovarian tissues; MSP, methylation-specific polymerase chain reaction; MSRE-PCR, methylation-sensitive restriction enzyme-polymerase chain reaction; CCP-based FRET, cationic conjugated polymer (CCP)-based fluorescence resonance energy transfer (FRET); FIGO, International Federation of Gynecology and Obstetrics. NR, not reported the median or mean age in all patients.
The control group include 43 benign ovarian carcinoma and 80 healthy women in this study.
Others included Mucinous, Clear cell, and Endometrioid carcinomas.
In further analysis, we regarded the high-grade serous as Poorly differentiated., others as well and moderately differentiated.
This study include 45 ovarian tumor tissues, 40 normal ovarian tissues, and 20 serum samples.
Others included Mucinous, Clear cell, Endometrioid, and undifferentiated carcinomas.
This study include 102 ovarian cancer tissues, 85 benign ovarian tumor, and 30 normal ovarian.
Pathological stage was classified according to the tumor, lymph node, and metastasis (TNM) classification of the American Joint Committee on Cancer (AJCC).
This study only reported the mean ages of different histological type, but not reported the mean age of cancer in tumor and normal tissue.
Others included Mucinous, Clear cell, Endometrioid, undifferentiated, metastatic, and other carcinomas.
This study include 63 epithelial ovarian cancer tissues, 41 Metastatic tissues of pelvic and abdomen cavity, 15 Adjacent non-cancerous ovarian tissues, 20 Normal ovairan tissues.
Others included Mucinous, Clear cell, and Endometrioid carcinomas.
In further analysis, we regarded the G1+G2 as well and moderately differentiated, G3 as poorly differentiated.